Comparative efficacy and pharmacological heterogeneity of individual potassium-competitive acid blockers: A systematic review and network meta-analysis

Table 3 Results of meta-analysis for the potassium-competitive acid blocker vs proton pump inhibitor efficacy in clarithromycin-resistant Helicobacter pylori infections

Ref.	Year	Country	P-CAB	Comparator	Eradication success in P-CAB group	Eradication success in PPI group	Δ (%)	OR	95%CI
Murakami et al[18]	2016	Japan	VPZ	LPZ	82/100 (82.0)	46/115 (40.0)	+42.0%	6.83	3.63-12.86
Chey et al[3] (triple)	2022	United States/Europe	VPZ	LPZ	48/73 (65.8)	23/72 (31.9)	+33.9%	4.09	2.05-8.17
Chey et al[3] (dual)	2022	United States/Europe	VPZ	LPZ	39/56 (69.6)	23/72 (31.9)	+37.7%	4.89	2.30-10.40
Tan et al[37]	2024	China	KVP	ESO	121/145 (83.5)	97/126 (77.0)	+6.5%	1.51	0.83-2.76
Park et al[43]	2026	Korea	TPZ	LPZ	11/23 (47.8%)	11/31 (35.5%)	+12.3%	1.67	0.56-5.01
Pooled (random effects, 5 studies, n = 813)								3.32	1.79-6.16

P-CAB: Potassium-competitive acid blocker; PPI: Proton pump inhibitor; OR: Odds ratio; VPZ: Vonoprazan; KVP: Keverprazan; LPZ: Lansoprazole; ESO: Esomeprazole.